infusion (CIV) was associated with 10-fold increases in the number of circulating NK cells and 80100-fold increases in the number of circulating effector memory CD8 T cells (Sneller et al

infusion (CIV) was associated with 10-fold increases in the number of circulating NK cells and 80100-fold increases in the number of circulating effector memory CD8 T cells (Sneller et al., 2011;Waldmann et al., 2011). == Clinical trials using IL-15 in the treatment of cancer == Over 170 clinical trials have been initiated in treatment of cancer using different IL-15 preparations. yr ago, IL-15 was identified by our group and that of Grabstein in culture supernatants from two cell lines (Cv-1/EBNA and HuT-102) that stimulated proliferation of the cytokine-dependent T cell line CTLL-2 in the presence of antiIL-2 antibodies (Bamford et al., 1994;Burton et al., 1994;Grabstein et al., 1994). Since that discovery, there have been >6,000 papers and >170 clinical trials involving IL-15, which are beyond the scope of this review and extensively covered in numerous reviews (Tagaya et al., 1996;Waldmann 2003,2006,2014,2015,2018;Waldmann et al., 1998,2001;Fehniger and Caligiuri, 2001;Fehniger et al., 2002;Lodolce et al., 2002;Becknell and Caligiuri, 2005;Ma et al., 2006;Overwijk and Schluns, 2009;Rochman et al., 2009;Jakobisiak et al., 2011;Steel et al., 2012;Mishra et al., 2014;Anthony and Schluns, 2015;Pilipow et al., 2015;Patidar et al., 2016;Chopek et al., 2017;Robinson and EPZ-6438 (Tazemetostat) Schluns, 2017;Lin and Leonard, 2018). Rather, we present a discussion of compelling topics that focuses on IL-15 in the pathogenesis of autoimmune disorders and select malignancies and analyzes approaches to block disordered IL-15 actions. The second theme presented focuses on immunostimulatory aspects and translation of the dramatic effects of IL-15 on natural killer (NK) and CD8 T cells generation and function in development of rational combination therapies for cancer. IL-15 mRNA is expressed by many tissues; however, IL-15 protein is largely limited to monocytes, macrophages, and dendritic cells (Bamford et al., 1996a). Although some regulation of IL-15 protein production occurs with transcription, most control of expression is at translation (Bamford et al., 1996a,1996b). Transcription of IL-15 is stimulated by type Rabbit Polyclonal to ACOT1 I and II interferons, CD40 ligation, and TLR stimuli. IL-15 translation is impeded by multiple 5-untranslated region AUG sequences, a long signal peptide, and a negative regulatory element in the coding sequence C-terminus (Bamford et al., 1996b). Tight regulation of IL-15 expression is required because of its potency as an inflammatory cytokine. The heterotrimeric IL-15 receptor is composed of common gamma chain (c) subunit (CD132) shared with IL-2, IL-4, IL-7, IL-9, and IL-21; chain (c) subunit (IL-2R/IL-15R, CD122) shared with the IL-2 receptor; and a private IL-15specific subunit IL-15R (CD215;Fehniger and Caligiuri, 2001;Waldmann, 2006). IL-15 binding to IL-2/IL-15R/c heterodimer induces JAK1 activation that phosphorylates STAT3 via the chain and JAK3 that phosphorylates STAT5 (STAT5A, STAT5B) via the chain (Fig. 1;Mishra et al., 2014). == Figure 1. == IL-15 signaling pathways.IL-15, in one scenario at left, binds to the heterotrimeric receptor in cis (Zanoni et al., 2013;Mishra et al., 2014). At right, IL-15 binds to the high-affinity IL-15R subunit expressed on antigen-presenting cells and is presented in EPZ-6438 (Tazemetostat) trans to IL-2/IL-15R heterodimers on NK or CD8 T cells (Dubois et al., 2002). EPZ-6438 (Tazemetostat) Activation proceeds via three pathways. The first involves JAK1/3/STAT3/5 activation, with phosphorylated STAT proteins forming dimers trafficking to the nucleus for transcriptional activation. In the second IL-15 pathway, adaptor protein Shc binds to a phosphotyrosine residue on IL-2/IL-15R, resulting in activation of the Shc, Grb2, GAB2, P13K, and AkT signaling pathway (Mishra et al., 2014). In the third pathway, IL-15 signaling is associated with activation of Grb2 and SOS to form a Grb2/SOS complex that activates the RAS-RAF MAPK pathway involved in cellular proliferation. Collectively, these signaling pathways induce expression and activation of c-Myc, c-Fos, c-Jun, Bcl-2, Bcl-xL, Mcl-1, NF-B, and TNF (modified fromMishra et al., 2014). IL-15 and IL-2 have several common functions including facilitating development of NK cells that reflect their sharing of receptor components IL-2/IL-15R and c and their use of common JAK1/3 and STAT3/5 signaling (Carson et al., 1997;Geginat et al., 2003;Farag and Caligiuri, 2006;Waldmann, 2006;Huntington, 2014). However, NK cell development is fairly normal in the absence of IL-2, whereas IL-15 is required for EPZ-6438 (Tazemetostat) normal NK development. There are also distinctions between IL-2 and IL-15 in adaptive immune responses. IL-2 acts as a growth factor during initiation of immune responses but also has crucial roles in preventing immunity to self by termination of T cell immune responses by activation-induced cell death (AICD) and by action of regulatory T cells (T reg cells;Lenardo et al., 1999;Snow et al., 2010;Sakaguchi, 2011). In contrast, IL-15 has no major net effect on maintenance of T reg cell fitness. IL-15 provides a sustained immune response to invading pathogens by being EPZ-6438 (Tazemetostat) an antiapoptotic factor; in particular, in IL-15 transgenic mice, IL-2induced.